semaglutide tirzepatide weight loss vs for Treatment Semaglutide and Tirzepatide -For Weight

Tirzepatide treatment was not associated with increased risk of the MACE-4 outcome (HR of 0.80 (95% CI, 0.571.11)) (Fig

Alsalim W et al

Rubino DM, Greenway FL, Khalid U, et al

Tirzepatide's cardio-metabolic benefits, including improvements in blood pressure, lipids, and glycemic control, were demonstrated at 5, 10, and 15 mg in the SURMOUNT program (Jastreboff et al., NEJM 2022)

However, the caloric restriction literature is directly applicable because tirzepatide weight loss is fundamentally driven by reduced caloric intake

Disclaimer The information provided in this blog post is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment